Developments in Biological Standardization

Vol. 36 Washington DC, 1976  Freeze-Drying of Biological Products
Vol. 37 Geneva, 1976  Standardization of Cell Substrates for the Production of Virus Vaccines
Vol. 39 Geneva, 1977  Influenza Immunization
Vol. 40 Marburg, 1977  Standardization of Rabies Vaccines for Human Use Produced in Tissue Culture (Rabies III)
Vol. 41 Guadeloupe, 1978  Vaccines in the Developing Countries
Vol. 43 Brussels, 1978  Immunization: Benefit Versus Risk Factors
Vol. 44 Villars, 1979  Test methods for the Quality Control of Plasma Proteins
Vol. 45 San Antonio, 1979  The Standardization of Animals to Improve Biomedical Research, Production and Control
Vol. 46 Oxford, 1979  Third General Meeting of ESACT
Vol. 47 Bilthoven, 1980  Reassessment of Inactivated Poliomyelitis Vaccine
Vol. 49 Leetown, 1981  Fish Biologies: Serodiagnosics and Vaccines
Vol. 50 Heidelberg, 1981  The Use of Heteroploid and Other Cell Substrates for the Production of Biologicals
Vol. 51 Lyons, 1981  Immunization of Adult Birds with Inactivated Oil Adjuvant Vaccines
Vol. 52 Lyons, 1981  Herpes Virus of Man and Animal: Standardization of Immunological Procedures
Vol. 53 Dublin, 1982  Enteric Infections in Man and Animals: Standardization of Immunological Procedures
Vol. 54 Athens, 1982  Viral Hepatitis: Standardization in Immunoprophylaxis of Infections by Hepatitis Viruses
Vol. 55 Copenhagen, 1982  Fifth General Meeting of ESCAT
Vol. 56 Algiers, 1983  Third International Symposium on Brucellosis
Vol. 57 Paris, 1983  Monoclonal Antibodies: Standardization of their Characterization and Use
Vol. 58 Budapest, 1983  International Symposium on BCG Vaccines and Tuberculins
Vol. 59 Geneva, 1983  Standardization and Control of Biologicals Produced by Recombinant DNA Technology
Vol. 60 Gardone Riviera, 1984  Production and Exploitation of Existing and New Animal Cell Substrates
Vol. 62 Stockholm, 1985  Diagnostics and Vaccines for Parasitic Diseases
Vol. 63 San Francisco, 1985  Use and Standardization of Chemically Defined Antigens
Vol. 64 London, 1985  Reduction of Animal Usage in the Development and Control of Biological Products
Vol. 65 Amsterdam, 1985  Use and Standardization of Combined Vaccines
Vol. 67 Melbourne, 1986  Standardization in Blood Fractionation Including Coagulation Factors
Vol. 68 Geneva, 1986  Cells - Products - Safety
Vol. 69 London, 1987  Cytokines Laboratory and Clinical Evaluation
Vol. 70 Arlington, VA, 1988  Continuous Cell Lines as Substrates for Biologicals
Vol. 71 Utrecht, 1989  Monoclonal Antibodies for Therapy, Prevention and In vivo Diagnosis of Human Disease
Vol. 72 Annecy, 1989  Progress in Animal Retroviruses
Vol. 73 Shizuoka, 1990  Pertussis: Evaluation and Research on Acellular Pertussis Vaccines
Vol. 74 Bethesda, MD, 1990  Biological Product Freeze-Drying and Formulation
Vol. 75 London, 1990  Virological Aspects of the Safety of Biological Products
Vol. 76 Bethesda, MD, 1991  Continuous Cell Lines - An International Workshop on Current Issues
Vol. 77 Annecy, 1991  Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators
Vol. 78 Bethesda, MD, 1991  Poliovirus Attenuation: Molecular Mechanisms and Practical Aspects
Vol. 79 Ploufragan, 1992  The First Steps Towards an International Harmonization of Veterinary Biologicals: 1993 and Free Circulation of Vaccines within the EEC
Vol. 80 Heidelberg, 1992  Transmissible Spongiform Encephalopathies - Impact on Animal and Human Health
Vol. 81 Cannes, 1992  Virological Safety Aspects of Plasma Derivatives
Vol. 82 Albany NY, 1993  Recombinant Vectors in Vaccine Development
Vol. 83 Annecy, 1993  Genetic Stability and Recombinant Product Consistency
Vol. 84 Langen, 1993  Non-Target Effects of Live Vaccines
Vol. 85 Santa Fé, NM, 1994  Genetics of Streptococci, Enterococci and Lactococci
Vol. 86 Langen, 1994  Replacement, Reduction and Refinement of Animal Experiments in the Development and Control of Biological Products
Vol. 87 Geneva, 1995  New Approaches to Stabilisation of Vaccines Potency
Vol. 88 Bethesda, MD, 1995  Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products
Vol. 89 Rome, 1995  Pertussis Vaccine Trials
Vol. 90 Oslo, 1996  Fish Vaccinology
Vol. 91 San Francisco, CA, 1996  Development of Specifications for Biotechnology Pharmaceuticals
Vol. 92 Bergen, 1996  Modulation of the Immune Response to Vaccine Antigens
Vol. 93 Annecy, 1996  Safety of Biological Products Prepared from Mammalian Cell Culture
Vol. 94 Bethesda, MD, 1997  Simian Virus 40 (SV-40): A Possible Human Polyomavirus
Vol. 95 Paris, 1997  Preclinical and Clinical Development of New Vaccines
Vol. 96 Washington, DC, 1995  Characterization of Biotechnology Pharmaceutical Products
Vol. 97 London, 1997  Biological Characterization and Assay of Cytokines and Growth Factors
Vol. 98 London, 1997  Inactivated Influenza Vaccines Prepared in Cell Culture
Vol. 100 Geneva, 1998  A Celebration of 50 Years of Progress in Biological Standardization and Control at WHO
Vol. 101 London, 1998  Alternatives to Animals in the Development and Control of Biological Products for Human and Veterinary Use
Developments in Biologicals

Vol. 102  San Francisco, CA, 1999  Advances in Transfusion Safety
Vol. 103  Annecy, 1999  Physico-Chemical Procedures for the Characterization of Vaccines
Vol. 104  Langen, 1999  Development and Clinical Progress of DNA Vaccines
Vol. 106  Rockville, MD, 2000  Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development
Vol. 107  London, 2000  The Design and Analysis of Potency Assays for Biotechnology Products
Vol. 108  Langen, 2001  Advances in Transfusion Safety
Vol. 110  Palm Cove, 2001  Orphan Vaccines – Bridging the Gap
Vol. 111  Utrecht, 2001  Advancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccines and Hormones
Vol. 112  Bethesda, MD, 2001  Immunogenicity of Therapeutic Biological Products
Vol. 113  Berlin, 2001  Process Validation for Manufacturing of Biologics and Biotechnology Products
Vol. 114  Ames, IA, 2002  Vaccines for OIE List A and Emerging Animal Diseases
Vol. 115  Bergen, 2002  Laboratory Correlates of Immunity to Influenza – A Reassessment, Development of Therapeutic Cancer Vaccines
Vol. 116  Los Angeles, CA, 2003  Consideration of Alternative Licensing Procedures for Vaccines for Minor Species, Minor Indications and Autogenous/Autologous Products
Vol. 117  Langen, 2003  Process Validation for Manufacturing of Biologics and Biotechnology Products
Vol. 118  Langen, 2003  PDA/EMEA European Virus Safety Forum
Vol. 119  Buenos Aires, 2004  Control of Infectious Animal Diseases by Vaccination
Vol. 120  Bethesda, MD, 2003  Advances in Transfusion Safety
Vol. 121  Bergen, 2003  Progress in Fish Vaccinology
Vol. 123  Rockville, MD, 2004  Vaccine Cell Substrates 2004
Vol. 125  Kiev, Ukraine, 2005  First International Conference on Rabies in Europe
Vol. 126  Saint-Malo, France, 2005  New Diagnostic Technology: Applications in Animal Health and Biologics Controls
Vol. 127  Sydney, Australia, 2005  Advances in Transfusion Safety – Volume IV
Vol. 128  Florianopolis, Brazil, 2006  First International Conference of the OIE Reference Laboratories and Collaborating Centres
Vol. 129  Bergen, Norway, 2006  The OIE Global Conference on Aquatic Animal Health
Vol. 130  Verona, Italy, 2007  Vaccination: A Tool for the Control of Avian Influenza
Vol. 131  Paris, France, 2007  Towards the Elimination of Rabies in Eurasia